

Subject card

| Subject name and code | Smart Biopharmaceuticals, PG_00058280 | | | | | | | | | |
|---|---|---|---|-------------------------------------|----------|---|---------|-----|--|--|
| Field of study | Biotechnology | | | | | | | | | |
| Date of commencement of studies | October 2022 | | Academic year of realisation of subject | | | 2023/2024 | | | | |
| Education level | second-cycle studies | | Subject group | | | Optional subject group | | | | |
| Mode of study | Full-time studies | | Mode of delivery | | | at the university | | | | |
| Year of study | 2 | | Language of instruction | | | Polish | | | | |
| Semester of study | 3 | | ECTS credits | | | 2.0 | | | | |
| Learning profile | general academic profile | | Assessment form | | | assessment | | | | |
| Conducting unit | Department of Pharmaceutical Technology and Biochemistry -> Faculty of Chemistry | | | | | | | | | |
| Name and surname | <u> </u> | | prof. dr hab. inż. Sławomir Milewski | | | | | | | |
| of lecturer (lecturers) | Teachers | | prof. dr hab. i | nż. Sławomir M | lilewski | | | | | |
| Lesson types and methods of instruction | Lesson type | Lecture | Tutorial | Laboratory | | | Seminar | SUM | | |
| | Number of study hours | 15.0 | 0.0 | 0.0 | 0.0 | | 15.0 | 30 | | |
| | E-learning hours included: 0.0 | | | | | | | | | |
| Learning activity and number of study hours | Learning activity | Participation in classes include plan | | Participation in consultation hours | | Self-study St | | SUM | | |
| | Number of study hours | 30 | | 2.0 | | | | 50 | | |
| Subject objectives | This course is a source of knowledge on modern second generation biopharmaceuticals exhibiting highselectivity due to the presence of fragments responsible for the targeted action of an active component. | | | | | | | | | |
| Learning outcomes | Course outcome Subject outcome | | | | | Method of verification | | | | |
| | [K7_W06] has knowledge about modern forms of drugs, including drugs of plant origin, new generation vaccines, alternative forms of therapy based on phages, knows issues related to biological activity of plant chemicals, knows how to test new drugs and how to introduce them to the market | | The student is able to give examples of second-generation biopharmaceuticals and explain the molecular basis of their targeted biological action. | | | [SW3] Assessment of knowledge contained in written work and projects [SW1] Assessment of factual knowledge | | | | |
| | [K7_K02] is aware of the limitations and the necessity of continuous development of knowledge and technology; understands the need for education and constant training | | Students, working in groups, analyze the state of knowledge about specific biopharmaceuticals and present the result of this analysis in a synthetic way. | | | [SK1] Assessment of group work skills [SK2] Assessment of progress of work | | | | |
| | [K7_U10] is able to use knowledge about possibilities, aims and limitations of biotechnology to develop, design and obtain products and biotechnological processes in the area of his/her specialization | | The student has acquired knowledge at an advanced level regarding the possibilities of designing structures of second generation biopharmautics and their production using biotechnological methods. | | | [SU3] Assessment of ability to use knowledge gained from the subject [SU4] Assessment of ability to use methods and tools | | | | |
| | [K7_U04] is able to predict potential properties of biomolecules and biologically active compounds on the basis of knowledge of their chemical structure and apply methods of molecular modelling of biomolecules | | Student is able to identify structural features of a given biopharmaceutic conditioning its biological properties. Student indicates alternative posibilities of modification of structure of a given biopharamaceutic towards changing a particular biological property. | | | [SU2] Assessment of ability to analyse information [SU3] Assessment of ability to use knowledge gained from the subject | | | | |

Data wydruku: 19.05.2024 22:44 Strona 1 z 2

| Subject contents | Drug targeting - strategies and ways of execution Strategies of improvement of properties, including selective toxicity of antimicrobials and anticancer drugs Mechanisms of microbial drug resistance and strategies of its overcoming Drug carriers - classes and applications Strategies of construction of drug conjugates Modern methods of construction and modification of proteinous biopharmaceuticals Design and preparation of drugs based on antibodies and antibody fragments Medicinal preparations based on DNA and mRNA | | | | | |
|--|---|---|-------------------------------|--|--|--|
| Prerequisites and co-requisites | Basic knowledge on low molecular weight, proteinous and nucleic acids-based biopharmaceuticals gained during first-cycle studies. | | | | | |
| Assessment methods and criteria | Subject passing criteria | Passing threshold | Percentage of the final grade | | | |
| | assessment of own presentation and activity during seminars | 50.0% | 40.0% | | | |
| | Written tests on lecture materials | 50.0% | 60.0% | | | |
| Recommended reading | Basic literature | D.J.A. Crommelin, R.D. Sindelar, B. Meibohm (eds). Pharmaceutical Biotechnology. Fundamentals and Applications. Fifth edition, Springer, New York, 2019 | | | | |
| | Supplementary literature | R.J.Y Ho and M. Gibaldi (eds.) Biotechnology and Biopharmaceuticals, John Wiley &Sons Inc., Hoboken, 2003 | | | | |
| | eResources addresses | Podstawowe https://www.scribd.com/document/459255962/2019-Book- PharmaceuticalBiotechnology-pdf - The pdf version of Pharmaceutical Biotechnology. Fundamentals and Applications. Fifth edition, Springer, New York, 2019 textbook Adresy na platformie eNauczanie: | | | | |
| Example issues/ example questions/ tasks being completed | Drug targeting - examples Structural modifications of antimicrobial drugs - goals and ways to achieve them Classes of drug carriers Linkers used in construction of drug conjugates Techniques of preparation drug:antibody conjugates Modifications of oligonucleotides aimed at their protection against nucleases | | | | | |
| Work placement | Not applicable | | | | | |

Data wydruku: 19.05.2024 22:44 Strona 2 z 2